Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Miguel Sogbe, Idoia Bilbao, Francesco P. Marchese, Jon Zazpe, Annarosaria De Vito, Marta Pozuelo, Delia D’Avola, Mercedes Iñarrairaegui, Carmen Berasain, Maria Arechederra, Josepmaria Argemi, Bruno Sangro

Clin Mol Hepatol. 2024;30(2):177-190. Published online December 29, 2023

Web of Science 6 Crossref 7

DOI: https://doi.org/10.3350/cmh.2023.0426

Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients

Jinlin Hou, Edward Gane, Rozalina Balabanska, Wenhong Zhang, Jiming Zhang, Tien Huey Lim, Qing Xie, Chau-Ting Yeh, Sheng-Shun Yang, Xieer Liang, Piyawat Komolmit, Apinya Leerapun, Zenghui Xue, Ethan Chen, Yuchen Zhang, Qiaoqiao Xie, Ting-Tsung Chang, Tsung-Hui Hu, Seng Gee Lim, Wan-Long Chuang, Barbara Leggett, Qingyan Bo, Xue Zhou, Miriam Triyatni, Wen Zhang, Man-Fung Yuen

Clin Mol Hepatol. 2024;30(2):191-205. Published online January 8, 2024

Web of Science 2 Crossref 3

DOI: https://doi.org/10.3350/cmh.2023.0422

JCAD deficiency attenuates activation of hepatic stellate cells and cholestatic fibrosis

Li Xie, Hui Chen, Li Zhang, Yue Ma, Yuan Zhou, Yong-Yu Yang, Chang Liu, Yu-Li Wang, Ya-Jun Yan, Jia Ding, Xiao Teng, Qiang Yang, Xiu-Ping Liu, Jian Wu

Clin Mol Hepatol. 2024;30(2):206-224. Published online January 8, 2024

Web of Science 5 Crossref 5

DOI: https://doi.org/10.3350/cmh.2023.0506

Prognosis of biopsy-confirmed metabolic dysfunction- associated steatotic liver disease: A sub-analysis of the CLIONE study

Michihiro Iwaki, Hideki Fujii, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata, Tsubasa Tsutsumi, Koji Sawada, Tatsuji Maeshiro, Hiroshi Tobita, Yuichi Yoshida, Masafumi Naito, Asuka Araki, Shingo Arakaki, Takumi Kawaguchi, Hidenao Noritake, Masafumi Ono, Tsutomu Masaki, Satoshi Yasuda, Eiichi Tomita, Masato Yoneda, Akihiro Tokushige, Yoshihiro Kamada, Hirokazu Takahashi, Shinichiro Ueda, Shinichi Aishima, Yoshio Sumida, Atsushi Nakajima, Takeshi Okanoue, Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG-NAFLD)

Clin Mol Hepatol. 2024;30(2):225-234. Published online January 24, 2024

Web of Science 6 Crossref 8

DOI: https://doi.org/10.3350/cmh.2023.0515

Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis

Michael H. Le, David M. Le, Thomas C. Baez, Hansen Dang, Vy H. Nguyen, KeeSeok Lee, Christopher D. Stave, Takanori Ito, Yuankai Wu, Yee Hui Yeo, Fanpu Ji, Ramsey Cheung, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):235-246. Published online January 26, 2024

Web of Science 14 Crossref 16

DOI: https://doi.org/10.3350/cmh.2023.0485

Identification of signature gene set as highly accurate determination of metabolic dysfunction-associated steatotic liver disease progression

Sumin Oh, Yang-Hyun Baek, Sungju Jung, Sumin Yoon, Byeonggeun Kang, Su-hyang Han, Gaeul Park, Je Yeong Ko, Sang-Young Han, Jin-Sook Jeong, Jin-Han Cho, Young-Hoon Roh, Sung-Wook Lee, Gi-Bok Choi, Yong Sun Lee, Won Kim, Rho Hyun Seong, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):247-262. Published online January 26, 2024

Web of Science 6 Crossref 7

DOI: https://doi.org/10.3350/cmh.2023.0449

Letters to the Editor

Changing from NAFLD to MASLD: Similar prognosis of patients with HCC under atezolizumab/bevacizumab treatment between NAFLD and MASLD

Hiroyuki Suzuki, Shigeo Shimose, Hideki Iwamoto, Takashi Niizeki, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):263-265. Published online January 18, 2024

Web of Science 5 Crossref 6

DOI: https://doi.org/10.3350/cmh.2023.0557

Tsubasa Tsutsumi, Dan Nakano, Machiko Kawaguchi, Hirokazu Takahashi, Takumi Kawaguchi

Clin Mol Hepatol. 2024;30(2):266-268. Published online January 30, 2024

Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.0028

Letter regarding “Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation”

Yun-Fan Liaw

Clin Mol Hepatol. 2024;30(2):269-271. Published online January 31, 2024

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.0064

Correspondences

Letter: Cardiovascular risk of tenofovir disoproxil fumarate or tenofovir alafenamide fumarate in patients with chronic hepatitis B: More questions than an answer – author’s reply

Hyeyeon Hong, Jonggi Choi

Clin Mol Hepatol. 2024;30(2):272-273. Published online February 21, 2024

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.0123

Correspondence on Letter regarding “Toward hepatitis C virus elimination using artificial intelligence”

Ming-Ying Lu, Ming-Lung Yu

Clin Mol Hepatol. 2024;30(2):274-275. Published online March 5, 2024

Web of Science 2 Crossref 2

DOI: https://doi.org/10.3350/cmh.2024.0152

Optimizing off-treatment outcome predictions: The potential of time-varying HBcrAg and the need for more research

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):276-278. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0220

Both liver parenchymal and non-parenchymal cells express JCAD protein under various circumstances

Li Xie, Li Zhang, Hui Chen, Yong-Yu Yang, Jian Wu

Clin Mol Hepatol. 2024;30(2):279-280. Published online March 20, 2024

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.0191

Correspondence on Letter regarding “Prognosis of biopsy-confirmed MASLD: A sub-analysis of the CLIONE study”

Hideki Fujii, Michihiro Iwaki, Yoshihiro Kamada

Clin Mol Hepatol. 2024;30(2):281-283. Published online April 1, 2024

Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.0214

In response to: Steatotic liver disease-know your enemies

Michael H. Le, Linda Henry, Mindie H. Nguyen

Clin Mol Hepatol. 2024;30(2):284-286. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0108

Correspondence on Editorial regarding “Identification of signature gene set as highly accurate determination of MASLD progression”

Sungju Jung, Sumin Yoon, Jong Hoon Park, Yeon-Su Lee, Kyung Hyun Yoo

Clin Mol Hepatol. 2024;30(2):287-290. Published online February 23, 2024

Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.0136

Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis”

Haeryoung Kim, Sook-Hyang Jeong

Clin Mol Hepatol. 2024;30(2):291-292. Published online March 19, 2024

Web of Science 1 Crossref 1

DOI: https://doi.org/10.3350/cmh.2024.0180

Harnessing hepatitis B core-related antigen measurement to optimize posttreatment monitoring

Ying-Nan Tsai, Jia-Ling Wu, Yao-Chun Hsu

Clin Mol Hepatol. 2024;30(2):293-296. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0101

Reply to Correspondence

Correspondence on Letter regarding “Both liver parenchymal and non-parenchymal cells express JCAD proteins under various circumstances”

Byoung Kuk Jang

Clin Mol Hepatol. 2024;30(2):297-298. Published online April 1, 2024

DOI: https://doi.org/10.3350/cmh.2024.0210

Snapshot

Immunopathogenesis of liver fibrosis in steatotic liver disease

Chaerin Woo, Won-Il Jeong

Clin Mol Hepatol. 2024;30(2):299-302. Published online February 19, 2024

DOI: https://doi.org/10.3350/cmh.2024.0113

Viewed By 5070	Examining the therapeutic landscape of beta-blockers in portal hypertension
Viewed By 5065	MAFLD: How is it different from NAFLD?
Viewed By 4484	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4448	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4356	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Cited By 248	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 198	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 145	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 137	MAFLD: How is it different from NAFLD?
Cited By 113	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach

Previous issues